NEW YORK (GenomeWeb) – Cancer molecular diagnostics firm Paradigm today said that it and preferred provider organization Stratose have entered into a contract to cover the PCDx test. 

Stratose, based in Atlanta, has more than 850,000 direct and affiliate contracts with providers nationwide. Stratose's members will now have access to the PCDx next-generation sequencing-based test, which identifies the underlying genomic and proteomic mutations in a patient's tumor DNA, RNA, and proteins. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.

May
11
Sponsored by
PerkinElmer

This webinar will provide an overview of an RNA-seq protocol that has been optimized to study small RNA species such as microRNAs.

May
23
Sponsored by
Agilent Technologies

This webinar will discuss a target enrichment workflow for high-confidence detection of variants. 

Jun
20
Sponsored by
OmniSeq

This webinar will discuss RNA sequencing as an alternative to immunohistochemistry (IHC) in selecting patients for cancer immunotherapy.